SCRIP
CITELINE COMMERCIAL

15 May 2023 | **News**

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: J&J's Duarto on the importance of diversity; Teva's views on its new risperidone launch; Almirall's hopes for lebrikizumab; Biogen's Viehbacher questions the need for spending on weight loss drugs; and Citeline's annual R&D review looks at the current state of the global biopharma pipeline.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip*'s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 12 May 2023, including: *Johnson & Johnson*'s Duato on the importance of diversity; *Teva Pharmaceutical Industries Ltd.*'s views on its new risperidone launch; *Almirall SA*'s hopes for lebrikizumab; *Biogen, Inc.*'s Viehbacher questions the need for spending on weight loss drugs; and *Citeline*'s annual R&D review looks at the current state of the global biopharma pipeline.

This and all our other podcasts are available on the Pharma Intelligence channel on *Apple Podcasts*, *Google Podcasts*, *SoundCloud*, *TuneIn* and *Spotify Podcasts*, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "*J&J CEO On Stereotypes, Innovation Secret Sauce And Kenvue*" - Scrip, 8 May, 2023.)
(Also see "*Teva Expects To Carve Out Sizable Niche For Uzedy In Antipsychotic Market*" - Scrip, 10 May, 2023.)

(Also see "*Almirall On Alert As Lebrikizumab Approval Date Approaches*" - Scrip, 9 May, 2023.)

(Also see "*Biogen CEO Poses Million Dollar Question – Do We Need To Spend On Weight Loss*

© Citeline 2024. All rights reserved.

Drugs?" - Scrip, 10 May, 2023.)

(Also see "*Oncology's Hold Over The Pharma Pipeline Increases As Growth Slows*" - Scrip, 8 May, 2023.)

Click here to explore this interactive content online

© Citeline 2024. All rights reserved.